How do I buy Editas Medicine Inc. (EDIT) stock?

Buying Editas Medicine Inc. (EDIT) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and verify your identity. Make a deposit. Search for the code "EDIT", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy EDIT by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

What is the minimum investment for EDIT on Gotrade?

On Gotrade , you don't have to buy a full share. With fractional shares, you can start investing in Editas Medicine Inc. from just $1. A small budget shouldn't stop you from building a US stock portfolio.

Does Editas Medicine Inc. (EDIT) pay dividends?

At the moment, Editas Medicine Inc. (EDIT) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track EDIT's performance via the price chart in the Gotrade app.

Is buying EDIT on Gotrade safe and legal?

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

What are the market hours to buy EDIT?

You can place an order any time. It goes through when the US market (NYSE/NASDAQ) opens: 9:30 AM to 4:00 PM New York time, Monday to Friday. Pre-market and after-hours trading are open too. The market is closed on US public holidays. The Gotrade app shows whether the market is open.

How do I tell if EDIT is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Editas Medicine Inc. (EDIT) Stock Price: Nov 11 Close $2.38

Latest news

Stocktwits

PRME, BEAM, EDIT, NTLA, CRSP Stocks Gain As FDA Signals Faster Route For Patient-Specific Gene Edits

EDITOctober 28, 2026

Stocktwits

PRME, BEAM, EDIT, NTLA, CRSP Stocks Gain As FDA Signals Faster Route For Patient-Specific Gene Edits

EDIT

Zacks Investment Research

EDIT Set to Begin First-in-Human Study in Hypercholesterolemia

PositiveEDITOctober 9, 2026

Zacks Investment ResearchPositive

EDIT Set to Begin First-in-Human Study in Hypercholesterolemia

EDIT

Stocktwits

Editas Medicine Gets Clearance For First Human Trial Of Gene-Editing Drug – Wells Fargo Sees Potential For Major Value Upside In 2027

EDITOctober 8, 2026

Stocktwits

Editas Medicine Gets Clearance For First Human Trial Of Gene-Editing Drug – Wells Fargo Sees Potential For Major Value Upside In 2027

EDIT

Stocktwits

CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?

EDITSeptember 23, 2026

Stocktwits

CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?

EDIT

MarketBeat

News tone: automated (AI) classification of the article's content, not a price prediction.

About Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

SectorHealthcare

IndustryBiotechnology

Employees87

CEODr. Gilmore O'Neill M.D.

IPO DateFeb 3, 2016

HeadquartersCambridge, MA

Key Executives

Name	Title	Year Born
Dr. Gilmore O'Neill M.D.	President, CEO & Director	1964
Ms. Amy Parison	Senior VP & CFO	1986
Dr. Linda C. Burkly Ph.D.	Executive VP & Chief Scientific Officer	1957
Dr. Feng Zhang Ph.D.	Co-Founder & Scientific Advisory Board Member	—
Dr. George McDonald Church Ph.D.	Co-Founder & Scientific Advisory Board Member	1954
Mr. Gregory Whitehead	Executive VP and Chief Technical & Quality Officer	—
Mr. Damien Grierson J.D.	Senior VP, General Counsel & Corporate Secretary	—
Mr. Tom Love	Vice President of People	—
Mr. Frank Panaccio	Senior VP & Chief Business Officer	—
Ms. Brieana Buckley	Senior Vice President of Development and Program Leadership	—

Fundamentals

Valuation

Price-to-sales ratio9.94

Price-to-book value4.57

PEG ratio0.00

Profitability

Return on Equity-130.00%

Return on Assets-36.00%

Return on Sales-152.00%

Gross margin (latest quarter)100.00%

EBITDA$-73.61M

Trading

Average volume2,148,910

Source: third-party data provider, as of November 13, 2026

Technical indicators

RSI 14: 42.99
MACD 12/26/9: -0.03
EMA 9 of MACD: -0.02
MACD histogram: -0.01
SMA 50: $2.67; Price below SMA 50
EMA 50: $2.67; Price below EMA 50
SMA 200: $2.70; Price below SMA 200
EMA 200: $2.63; Price below EMA 200

Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.

Analyst views

2 analyst ratings

Third-party analyst opinion, not a recommendation from Gotrade.

Analyst consensus:Buy

100% Buy

0% Hold

0% Sell

Analyst price target

Low: $5.00
Average: $5.50
High: $6.00

Guggenheim

Debjit Chattopadhyay

Buy

Target price

$5.00

Wells Fargo

Yanan Zhu

Buy

Target price

$6.00

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2021											-9.3	-12.7
2022	-31.1	-13.1	+8.7	-34.5	-20.2	+7.8	+26.4	-7.2	-20.6	+1.8	-16.9	-11.8
2023	+17.2	-13.2	-16.9	+15.3	+10.6	-13.8	+6.6	+3.0	-14.1	-6.4	+52.6	-5.9
2024	-29.6	+39.3	-29.5	-28.4	-4.9	-13.7	+17.4	-27.2	-2.3	-11.3	-23.0	-42.0
2025	+0.0	+51.2	-34.5	+46.0	+6.2	+24.3	+11.6	+5.3	+40.5	-13.2	-21.2	-6.4
2026	-2.9	+9.5	+14.9	+14.9	+19.3	-3.0	-21.3	+15.5	-16.3	+6.0	-7.4

Compare stocks

EDIT

Buy EDIT

Market cap

$367.33M

-

Price / Earnings ratio

-5.40

-

Price / Sales ratio

9.94

-

Dividend yield

0.00%

-

Average volume

2,148,910

-

Earnings per share

$-0.56

-

Editas Medicine Inc. (EDIT) Stock

Key stats

Compare with EDIT

Recent news

PRME, BEAM, EDIT, NTLA, CRSP Stocks Gain As FDA Signals Faster Route For Patient-Specific Gene Edits

PRME, BEAM, EDIT, NTLA, CRSP Stocks Gain As FDA Signals Faster Route For Patient-Specific Gene Edits

EDIT Set to Begin First-in-Human Study in Hypercholesterolemia

EDIT Set to Begin First-in-Human Study in Hypercholesterolemia

Editas Medicine Gets Clearance For First Human Trial Of Gene-Editing Drug – Wells Fargo Sees Potential For Major Value Upside In 2027

Editas Medicine Gets Clearance For First Human Trial Of Gene-Editing Drug – Wells Fargo Sees Potential For Major Value Upside In 2027

CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?

CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?

Technical indicators

Analyst ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

PRME, BEAM, EDIT, NTLA, CRSP Stocks Gain As FDA Signals Faster Route For Patient-Specific Gene Edits

PRME, BEAM, EDIT, NTLA, CRSP Stocks Gain As FDA Signals Faster Route For Patient-Specific Gene Edits

EDIT Set to Begin First-in-Human Study in Hypercholesterolemia

EDIT Set to Begin First-in-Human Study in Hypercholesterolemia

Editas Medicine Gets Clearance For First Human Trial Of Gene-Editing Drug – Wells Fargo Sees Potential For Major Value Upside In 2027

Editas Medicine Gets Clearance For First Human Trial Of Gene-Editing Drug – Wells Fargo Sees Potential For Major Value Upside In 2027

CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?

CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?

Editas Medicine Targets 2026 Patient Dosing for LDL Gene-Editing Therapy

Editas Medicine Targets 2026 Patient Dosing for LDL Gene-Editing Therapy

Editas Medicine Eyes First Human Trial for CRISPR Cholesterol Therapy EDIT-401

Editas Medicine Eyes First Human Trial for CRISPR Cholesterol Therapy EDIT-401

Editas (EDIT) Up 6.2% Since Last Earnings Report: Can It Continue?

Editas (EDIT) Up 6.2% Since Last Earnings Report: Can It Continue?

Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year?

Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year?

EDIT Q2 Earnings Beat Estimates, Revenues Rise, Pipeline in Focus

EDIT Q2 Earnings Beat Estimates, Revenues Rise, Pipeline in Focus

Editas Medicine (EDIT) Reports Q2 Loss, Beats Revenue Estimates

Editas Medicine (EDIT) Reports Q2 Loss, Beats Revenue Estimates

About Editas Medicine Inc.

Key Executives

Fundamentals

Valuation

Profitability

Trading

Technical indicators

Analyst views

Seasonality

Compare stocks

Market cap

Price / Earnings ratio

Price / Sales ratio

Dividend yield

Average volume

Earnings per share

Stocks in the same sector

FAQ

Trade Faster. Easier. Smarter.

#ReadyGoTrade